FDA Expands Wegovy Label to Include Heart Attack and Stroke Reduction

Key points

• The FDA approved Wegovy to cut the risk of heart attack, stroke, and cardiovascular death in overweight or obese adults with heart disease.
• A major clinical trial demonstrated a 20 percent reduction in major adverse cardiovascular events among participants taking the medication.
• The new heart health indication is expected to force public and private insurers to expand coverage for GLP-1 medications.
• Restaurants and food manufacturers are adjusting menus and products as consumer appetite patterns shift away from high fat and sugary options.

This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.

Sources and methodology

Reported from the public datasets below.

• Bureau of Labor Statistics (BLS) - Consumer Price Index, food away from home
• Federal Reserve Economic Data (FRED) - Food services and drinking places series
• U.S. Census Bureau - Monthly Retail Trade, food services

All sources Foodie Pundit reports from

More from the Foodie Pundit Newsroom

• Celebrity Chef Opening Marks Major Economic Level Up for Arlington Restaurant Scene
• Inside The Cocochine: How Mayfair Newest Luxury Table Strategy Unfolds
• FDA Approves Wegovy for Heart Disease Risk Reduction as Food Industry Prepares for Shift
• The End of the Table for One as Restaurants Pivot Back to Group Dining
• Bro’s Hot Chicken Reportedly Planning Miami Location Near FIU